Atara Biotherapeutics(ATRA) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Atara Biotherapeutics Announces Second Quarter 2024 Financial Results, Operational Progress and Leadership Update Tab-cel ® U.S. BLA Accepted Under Priority Review With PDUFA Action Date of January 15, 2025 ATA3219 Lupus Nephritis and Severe Systemic Lupus Erythematosus Study Initiation Expected Q4 2024; Initial Clinical Data Expected Mid-2025 Enrolling ATA3219 Non-Hodgkin's Lymphoma Study; Initial Clinical Data Expected Q1 2025 Effective September 9, 2024, Pascal Touchon To Assume Role of Chai ...